Amgen sets plan for bone drug

Amgen Inc. said it hoped to begin selling its bone drug denosumab next year, fueling growth as the decline in revenue from its top-selling anemia treatments bottoms out.

The company plans to file by the end of this year or early 2009 for U.S. approval of denosumab, Thousand Oaks-based Amgen has said.